G1 Therapeutics, Inc.

NasdaqGS:GTHX Stock Report

Market Cap: US$378.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

G1 Therapeutics Past Earnings Performance

Past criteria checks 0/6

G1 Therapeutics has been growing earnings at an average annual rate of 9.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 38.8% per year.

Key information

9.2%

Earnings growth rate

14.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate38.8%
Return on equity-182.1%
Net Margin-76.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Jul 26
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Jun 24

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27
Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08
New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04
The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04
Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

Revenue & Expenses Breakdown

How G1 Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:GTHX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2458-456129
31 Mar 2484-316535
31 Dec 2383-487243
30 Sep 2378-718052
30 Jun 2389-788863
31 Mar 2357-1269672
31 Dec 2251-14810183
30 Sep 2247-15410186
30 Jun 2228-17110187
31 Mar 2224-17110085
31 Dec 2131-1489675
30 Sep 2142-1349872
30 Jun 2164-1039269
31 Mar 2160-958168
31 Dec 2045-996972
30 Sep 2029-1095781
30 Jun 202-13050127
31 Mar 200-13044109
31 Dec 190-1224188
30 Sep 190-11135135
30 Jun 190-992970
31 Mar 190-892353
31 Dec 180-851970
30 Sep 180-78140
30 Jun 180-74110
31 Mar 180-68917
31 Dec 170-65754
30 Sep 170-6060
30 Jun 170-5250
31 Mar 170-4540
31 Dec 160-3550
31 Dec 151-2230
31 Dec 141-730

Quality Earnings: GTHX is currently unprofitable.

Growing Profit Margin: GTHX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GTHX is unprofitable, but has reduced losses over the past 5 years at a rate of 9.2% per year.

Accelerating Growth: Unable to compare GTHX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GTHX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).


Return on Equity

High ROE: GTHX has a negative Return on Equity (-182.05%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies